Skip to main content
SpringerLink
Log in

Absence of Germline and Somatic p53 Alterations in Children with Sporadic Brain Tumors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Cancers of the central nervous system are the most common solid tumors of childhood. Although somatic alterations of the p53 tumor suppressor gene have been implicated in brain tumorigenesis, the role of germline p53 mutations in the development of childhood brain tumors has not been well defined. As a component of an ongoing extensive study of the epidemiology of childhood brain tumors, we prospectively examined the germline and tumor p53 gene status in 85 children without a family history of cancer who were diagnosed with a sporadic malignant central nervous system tumor. Using PCR/single-strand conformational polymorphism analysis and direct DNA sequencing, 85 children were screened for the presence of constitutional p53 sequence alterations in exons 2 and 4 through 11. No mutations were identified. Commonly reported sequence polymorphisms were observed at codon 72, as well as in 2 other previously described nucleotide residues. Forty-four brain tumor samples were available for analysis and of these 40 were paired with peripheral blood. Once again, no p53 mutations were found. Of the 5 germline samples with the 2 common polymorphisms, only one had a paired tumor sample for comparison and the tumor contained the same alteration as the germline. Of note, one tumor, a PNET of the cerebellum (medulloblastoma), showed loss of heterozygosity at codon 72. We can conclude that the frequency of germline and somatic p53 mutations in sporadic childhood brain tumors is very low, probably less than 1%, and there is no need to screen these patients routinely for their germline p53 status. However, the potential significance of LOH at codon 72 remains to be elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pizzo P, Poplak D, (eds): Principles and Practice of Pediatric Oncology. 3rd edn., Lippincott-Raven, Philadelphia, 1997

    Google Scholar 

  2. Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71(4): 747–752, 1969

    Google Scholar 

  3. Li FP, Fraumeni JF Jr: Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43(6): 1365–1373, 1969

    Google Scholar 

  4. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF Jr, Li FP: Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51(22): 6094–6097, 1991

    Google Scholar 

  5. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff JZ, Tainsky MA, Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms (see comments). Science 250(4985): 1233–1238, 1990

    Google Scholar 

  6. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancerprone family with Li-Fraumeni syndrome (see comments). Nature 348(6303): 747–749, 1990

    Google Scholar 

  7. Frebourg T, Kassel J, Lam KT, Gryka MA, Barbier N, Andersen TI, Borresen AL, Friend SH: Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci USA 89(14): 6413–6417, 1992

    Google Scholar 

  8. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM: Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57(15): 3245–3252, 1997

    Google Scholar 

  9. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H: Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150(1): 1–13, 1997

    Google Scholar 

  10. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22(17): 3551–3555, 1994

    Google Scholar 

  11. McBride OW, Merry D, Givol D: The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83(1): 130–134, 1986

    Google Scholar 

  12. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88(3): 323–331, 1997

    Google Scholar 

  13. Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA: Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet 82(2): 106–115, 1995

    Google Scholar 

  14. Felix CA, Slavc I, Dunn M, Strauss EA, Phillips PC, Rorke LB, Sutton L, Bunin GR, Biegel JA: p53 gene mutations in pediatric brain tumors. Med Pediatr Oncol 25(6): 431–436, 1995

    Google Scholar 

  15. Orellana C, Hernandez-Marti M, Martinez F, Castel V, Millan JM, Alvarez-Garijo JA, Prieto F, Badia L: Pediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations. Cancer Genet Cytogenet 102(2): 93–99, 1998

    Google Scholar 

  16. Phelan CM, Liu L, Ruttledge MH, Muntzning K, Ridderheim PA, Collins VP: Chromosome 17 abnormalities and lack of TP53 mutations in paediatric central nervous system tumours. Hum Genet 96(6): 684–690, 1995

    Google Scholar 

  17. Biegel JA, Burk CD, Barr FG, Emanuel BS: Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 52(12): 3391–3395, 1992

    Google Scholar 

  18. Bhattacharjee MB, Bruner JM: p53 protein in pediatric malignant astrocytomas: a study of 21 patients. J Neuro-Oncol 32(3): 225–233, 1997

    Google Scholar 

  19. Kyritsis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS, Levin VA, Saya H: Germline p53 gene mutations in subsets of glioma patients (see comments). J Natl Cancer Inst 86(5): 344–349, 1994

    Google Scholar 

  20. Li YJ, Sanson M, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R: Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer 64(6): 383–387, 1995

    Google Scholar 

  21. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D: High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86(22): 1707–1710, 1994

    Google Scholar 

  22. Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DG, Harris M, Kelsey AM, Birch JM: Are there low-penetrance TP53 alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet 65(4): 995–1006, 1999

    Google Scholar 

  23. McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, Yan YX, Russo C, Sato J, Barbier N, Miser J, Malkin D, Gebhardt MC: Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12(5): 925–930, 1994

    Google Scholar 

  24. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D: Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95(4): 1606–1611, 1995

    Google Scholar 

  25. Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, Knutsen T, Minna JD: Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 89(2): 640–647, 1992

    Google Scholar 

  26. Borresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D, Friend SH: Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52(11): 3234–3236, 1992

    Google Scholar 

  27. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N: Inherited p53 gene mutations in breast cancer. Cancer Res 52(10): 2984–2986, 1992

    Google Scholar 

  28. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7(2): 961–963, 1987

    Google Scholar 

  29. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L: Is p53 polymorphism maintained by natural selection? Hum Hered 44(5): 266–270, 1994

    Google Scholar 

  30. Sjalander A, Birgander R, Saha N, Beckman L, Beckman G: p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 46(1): 41–48, 1996

    Google Scholar 

  31. Walker KK, Levine AJ: Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93(26): 15,335–15,340, 1996

    Google Scholar 

  32. Sakamuro D, Sabbatini P, White E, Prendergast GC: The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15(8): 887–898, 1997

    Google Scholar 

  33. Zhu J, Jiang J, Zhou W, Zhu K, Chen X: Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18(12): 2149–2155, 1999

    Google Scholar 

  34. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K: Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6(8): 1313–1318, 1991

    Google Scholar 

  35. Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, Jewett M, Buchanan J, Goss PE: Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53(15): 3574–3578, 1993

    Google Scholar 

  36. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6(12): 4650–4656, 1986

    Google Scholar 

  37. STATA-Statistics/Data Analysis (version 6), College Station, Texas: Stata Corporation, 1999

  38. Carbone D, Chiba I, Mitsudomi T: Polymorphism at codon 213 within the p53 gene. Oncogene 6(9): 1691–1692, 1991

    Google Scholar 

  39. Bhatia K, Gutierrez MI, Huppi K, Magrath IT: PCR detection of a neutral CGA/CGC dimorphism in exon 6 of the human p53 gene. Nucleic Acids Res 20(4): 928, 1992

    Google Scholar 

  40. Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC: Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 53(3): 752–759, 1993

    Google Scholar 

  41. Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KJ, Evans DG, Birch JM: A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14(7): 865–871, 1997

    Google Scholar 

  42. Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB, Andrulis IL: Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 4(6): 1089–1092, 1995

    Google Scholar 

  43. Avigad S, Barel D, Blau O, Malka A, Zoldan M, Mor C, Fogel M, Cohen IJ, Stark B, Goshen Y, Stein J, Zaizov R: A novel germline p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 14(13): 1541–1545, 1997

    Google Scholar 

  44. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, Shields PG, Modali R, Turner BC: Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 60(4): 1062–1069, 2000

    Google Scholar 

  45. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G: Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 86(4): 369–370, 1991

    Google Scholar 

  46. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19(2): 1092–1100, 1999 235

    Google Scholar 

  47. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S: Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14(6): 1085–1089, 1993

    Google Scholar 

  48. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR: Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16(9): 2205–2208, 1995

    Google Scholar 

  49. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L: p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17(6): 1313–1316, 1996

    Google Scholar 

  50. Murata M, Tagawa M, Kimura H, Kakisawa K, Shirasawa H, Fujisawa T: Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol 12(3): 577–581, 1998

    Google Scholar 

  51. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer (see comments). Nature 393(6682): 229–234, 1998

    Google Scholar 

  52. Tagawa M, Murata M, Kimura H: Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Lett 128(1): 93–99, 1998

    Google Scholar 

  53. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY: Prognostic significance of p53 codon 72 polymorphism in lung carcinomas (In Process Citation). Eur J Cancer 35(2): 226–230, 1999

    Google Scholar 

  54. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L: P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16(9): 2233–2236, 1995

    Google Scholar 

  55. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, Beckman G: P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16(7): 1461–1464, 1995

    Google Scholar 

  56. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ: p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352(9131): 871–872, 1998

    Google Scholar 

  57. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB: p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18(3B): 2095–2099, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

    Carol Portwine, Susan Chilton-MacNeill, Elizabeth Sexsmith, John McLaughlin & David Malkin

  2. Division of Epidemiology and Biostatistics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

    Catherine Brown

Authors
  1. Carol Portwine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Chilton-MacNeill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elizabeth Sexsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John McLaughlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Malkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Portwine, C., Chilton-MacNeill, S., Brown, C. et al. Absence of Germline and Somatic p53 Alterations in Children with Sporadic Brain Tumors. J Neurooncol 52, 227–235 (2001). https://doi.org/10.1023/A:1010661831335

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010661831335

Search

Navigation